Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus.
Jankowski
Janusz
J
Moayyedi
Paul
P
D000230:Adenocarcinoma / Q000191:economics / Q000517:prevention & control; D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000191:economics; D001241:Aspirin / Q000008:administration & dosage* / Q000191:economics*; D001471:Barrett Esophagus / Q000191:economics* / Q000401:mortality / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D016527:Drug Costs / Q000706:statistics & numerical data; D004359:Drug Therapy, Combination; D004938:Esophageal Neoplasms / Q000191:economics* / Q000517:prevention & control*; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000191:economics; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D006113:United Kingdom
D000897:Anti-Ulcer Agents; D009853:Omeprazole; D001241:Aspirin